Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, chairs a discussion with Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, and Caron Jacobson, MD, from the Dana-Farber Cancer Institute, Boston, MA, on the key news from day 2 of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France. The experts explore precision medicine and bridging treatment to CAR T-cell therapy; exciting strategies include combinations with polatuzumab vedotin or ibrutinib pre-treatment. A highlighted consideration is how prior treatment with common drugs affect later T-cell collection from patients.
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
